Melanoma Research Alliance: 2022-2023 RFP MRA 2022-2023 Request for Proposals - Now Open The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment. Proposals will be accepted for Established Investigator Awards, Academic-Industry Partnership Awards, Young Investigator Awards, and Pilot Awards. We intend to support at least $11.5 million in new funding through this RFP. Special Opportunities Included in RFP: Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS) Radiation Oncology Young Investigator Award co-funded with the American Society for Radiation Oncology (ASTRO) Metastatic Uveal Melanoma Pilot Award co-funded with A Cure in Sight Patient-Centric Clinical Trials Team Science Awards co-funded with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) Please Note the Following Key Deadlines: October 5: Letters of Intent Due for RTFCCR-MRA Team Science Awards on Patient-Centered Clinical Trials October 19: Young Investigator Award Eligibility Checklist Due November 2: Full Proposals Due All proposals are due by 11:59 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL on-line application tool: https://proposalcentral.com/. More Info LOI Due for RTFCCR-MRA Team Science Awards on Patient-Centered Clinical Trials: Oct 05, 2022 - 5:59:PM Young Investigator Award Eligibility Checklist Due: Oct 19, 2022 - 5:59:PM Full Proposals Due: Nov 02, 2022 - 5:59:PM Learn More Agency Melanoma Research Alliance Type Non-Federal Disciplines Early Career MRA 2022-2023 RFP MRA Award Terms and Conditions
Melanoma Research Alliance: 2022-2023 RFP MRA 2022-2023 Request for Proposals - Now Open The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment. Proposals will be accepted for Established Investigator Awards, Academic-Industry Partnership Awards, Young Investigator Awards, and Pilot Awards. We intend to support at least $11.5 million in new funding through this RFP. Special Opportunities Included in RFP: Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS) Radiation Oncology Young Investigator Award co-funded with the American Society for Radiation Oncology (ASTRO) Metastatic Uveal Melanoma Pilot Award co-funded with A Cure in Sight Patient-Centric Clinical Trials Team Science Awards co-funded with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) Please Note the Following Key Deadlines: October 5: Letters of Intent Due for RTFCCR-MRA Team Science Awards on Patient-Centered Clinical Trials October 19: Young Investigator Award Eligibility Checklist Due November 2: Full Proposals Due All proposals are due by 11:59 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL on-line application tool: https://proposalcentral.com/. More Info LOI Due for RTFCCR-MRA Team Science Awards on Patient-Centered Clinical Trials: Oct 05, 2022 - 5:59:PM Young Investigator Award Eligibility Checklist Due: Oct 19, 2022 - 5:59:PM Full Proposals Due: Nov 02, 2022 - 5:59:PM Learn More Agency Melanoma Research Alliance Type Non-Federal Disciplines Early Career MRA 2022-2023 RFP MRA Award Terms and Conditions